Keywords: genzyme, tkt, continue, fabry, battle, granted, co-orphan

Genzyme and TKT continue Fabry battle; granted co-orphan drug status in EU

Article | 07 August 2001

Transkaryotic Therapies and Genzyme General both won European Unionregulatory approval, on August 3, for their Fabry disease drugs, Fabrazyme (agalsidase alfa) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Genzyme

Go to company listing

Related Drugs

Agalsidase Beta

Fabrazyme

Cerezyme

Imiglucerase

Amino Acids

Go to drug listing